Our results indicated that the PI3K/AKT/mTOR signaling pathway inhibitor could reverse DCLK1-mediated tumor progression, suggesting that CCA populations with high DCLK1 expression may benefit from therapies targeting the PI3K/AKT/mTOR pathway. Here, DCLK1 is linked to cholangiocarcinoma.